These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26077423)

  • 1. Small molecule inhibitors of EZH2: the emerging translational landscape.
    Keilhack H; Smith JJ
    Epigenomics; 2015; 7(3):337-41. PubMed ID: 26077423
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
    Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
    Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2 as a potential target in cancer therapy.
    McCabe MT; Creasy CL
    Epigenomics; 2014 Jun; 6(3):341-51. PubMed ID: 25111487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
    Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
    J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
    Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer.
    Verma SK
    Curr Top Med Chem; 2015; 15(8):714-9. PubMed ID: 25732793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
    Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
    Li B; Chng WJ
    J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
    Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
    Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAH derived potent and selective EZH2 inhibitors.
    Kung PP; Huang B; Zehnder L; Tatlock J; Bingham P; Krivacic C; Gajiwala K; Diehl W; Yu X; Maegley KA
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1532-7. PubMed ID: 25746813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of cancer stem cells by inhibitors of DNA and histone methylation.
    Momparler RL; Côté S
    Expert Opin Investig Drugs; 2015; 24(8):1031-43. PubMed ID: 26004134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
    Yang CY; Wang S
    J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.
    Ansari A; Satalkar S; Patil V; Shete AS; Kaur S; Gupta A; Singh S; Raja M; Severance DL; Bernales S; Chakravarty S; Hung DT; Pham SM; Herrera FJ; Rai R
    Bioorg Med Chem Lett; 2017 Jan; 27(2):217-222. PubMed ID: 27923618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase.
    Simard JR; Plant M; Emkey R; Yu V
    Assay Drug Dev Technol; 2013 Apr; 11(3):152-62. PubMed ID: 23409774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Potential Epigenetic Therapy for NSCLC.
    Cancer Discov; 2015 Apr; 5(4):341. PubMed ID: 25724377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
    Lue JK; Amengual JE
    Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.